DVAX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DVAX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Dynavax Technologies's Enterprise Value is $1,050.9 Mil. Dynavax Technologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $2.7 Mil. Therefore, Dynavax Technologies's EV-to-EBIT for today is 394.05.
The historical rank and industry rank for Dynavax Technologies's EV-to-EBIT or its related term are showing as below:
During the past 13 years, the highest EV-to-EBIT of Dynavax Technologies was 533.10. The lowest was -89.90. And the median was -3.43.
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Dynavax Technologies's Enterprise Value for the quarter that ended in Dec. 2023 was $1,325.4 Mil. Dynavax Technologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $2.7 Mil. Dynavax Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 0.20%.
The historical data trend for Dynavax Technologies's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dynavax Technologies Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EV-to-EBIT | Get a 7-Day Free Trial | -4.02 | -9.67 | 16.25 | 3.29 | 554.58 |
Dynavax Technologies Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
EV-to-EBIT | Get a 7-Day Free Trial | 3.29 | 3.54 | 10.37 | 20.76 | 554.58 |
For the Drug Manufacturers - Specialty & Generic subindustry, Dynavax Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Dynavax Technologies's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Dynavax Technologies's EV-to-EBIT falls into.
Dynavax Technologies's EV-to-EBIT for today is calculated as:
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 1050.943 | / | 2.667 | |
= | 394.05 |
Dynavax Technologies's current Enterprise Value is $1,050.9 Mil.
Dynavax Technologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dynavax Technologies (NAS:DVAX) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.
Dynavax Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:
Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) | = | EBIT | / | Enterprise Value (Q: Dec. 2023 ) |
= | 2.667 | / | 1325.4414 | |
= | 0.20 % |
Dynavax Technologies's Enterprise Value for the quarter that ended in Dec. 2023 was $1,325.4 Mil.
Dynavax Technologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Dynavax Technologies's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Robert Janssen | officer: Chief Medical Officer and VP | C/O DYNAVAX TECHNOLOGIES, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710 |
David F Novack | officer: Senior Vice President | 39 YORKSHIRE DR, OAKLAND CA 94618 |
Hack Andrew A. F. | director | 300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142 |
Justin Burgess | officer: Principal Accounting Officer | C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 1900, EMERYVILLE CA 94608 |
Ryan Spencer | officer: Co-President and Senior VP | C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710-2753 |
Francis Cano | director | 11 ACORN LANE, LOS ALTOS CA 94022 |
Elaine D Sun | director | 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121 |
Scott Dunseth Myers | director | C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121 |
Kelly Macdonald | officer: SVP and CFO | 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110 |
Peter R. Paradiso | director | C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 900, EMERYVILLE CA 94608 |
Julia Marie Eastland | director | C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121 |
Brent Macgregor | director | C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 900, EMERYVILLE CA 94608 |
Peggy V Phillips | director | C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710 |
Robert Coffman | officer: Chief Science Officer and VP | C/O DYNAVAX TECHNOLOGIES CORP, 2929 SEVENTH ST STE 100, BERKELEY CA 94710 |
Michael S Ostrach | officer: VP, CBO, and General Counsel | 1300 SEAPORT BOULEVARD, REDWOOD CITY CA 94063 |
From GuruFocus
By PRNewswire • 10-26-2023
By PurpleRose PurpleRose • 08-25-2022
By PRNewswire PRNewswire • 02-28-2023
By PRNewswire • 10-19-2023
By PRNewswire • 01-04-2024
By PRNewswire PRNewswire • 10-14-2022
By PRNewswire • 09-06-2023
By PRNewswire PRNewswire • 04-18-2023
By PRNewswire PRNewswire • 11-09-2022
By GuruFocus Research • 01-05-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.